All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2021-03-26T09:44:08.000Z

What is the impact of chronic GvHD on first late effects in transplant survivors?

By Paola Frisone, Georgia Scurfield, Maria Kasimati
Featured
Catherine J. Lee
Mar 26, 2021
Share:

Bookmark this article

During the 2021 TCT Meetings Digital Experience, the GvHD Hub spoke to Catherine J. Lee, The University of Utah, Salt Lake City, US. We asked, what is the impact of chronic GvHD on first late effects in transplant survivors?

What is the impact of chronic GvHD on first late effects in transplant survivors?

Lee reports results from a study evaluating occurrence and type of first late effects, after hematopoietic cell transplantation, in 2-year disease-free patients with and without chronic graft-versus-host disease (GvHD).

 

More about...
Chronic graft-versus-host diseaseTCT 2021

Your opinion matters

HCPs, what is your preferred format for educational content on the GvHD Hub?
8 votes - 21 days left ...

Related articles

Add bookmark

Editorial theme | Latest updates on cGvHD treatment

First-line treatment for chronic graft-versus-host disease (cGvHD), which consists of steroids, has not changed much over the last three decades. In the case of severe cGvHD, another...

Apr 19, 2021
Add bookmark

Editorial theme | Latest updates on cGvHD treatment

First-line treatment for chronic graft-versus-host disease (cGvHD), which consists of steroids, has not changed much over the last three decades. In...

Apr 19, 2021
Add bookmark

How should we manage highly morbid forms of chronic GvHD?

During the 2021 TCT Meetings Digital Experience, the GvHD Hub spoke to Daniel Wolff, University Hospital Regensburg, Regensburg, DE. We asked, How should we manage highly morbid forms of...

Mar 4, 2021
Add bookmark

How should we manage highly morbid forms of chronic GvHD?

During the 2021 TCT Meetings Digital Experience, the GvHD Hub spoke to Daniel Wolff, University Hospital Regensburg, Regensburg, DE. We asked,...

Mar 4, 2021

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox